What is TB-500? A synthetic fragment of thymosin β4, not the complete protein. It acts on G-actin, promoting cell migration and angiogenesis, with an action described as more systemic than local. The only clinical trials in this family have been run in ophthalmic and dermal indications, not musculoskeletal ones.
Thymosin β4 versus the TB-500 fragment
Most short answers to what is TB-500 skip this distinction, and it changes how the entire literature reads.
Thymosin β4 (Tβ4) is a natural 43-amino-acid peptide found in nearly every mammalian cell. It is one of the most abundant proteins in the body, and its main job is sequestering G-actin, regulating the dynamics of the cytoskeleton.
TB-500 is a synthetic fragment corresponding to the region of the molecule associated with actin binding, roughly seven amino acids long.
The consequence of that difference is concrete and routinely ignored: most of the serious scientific literature was done with complete thymosin β4, not with the fragment. When commercial material cites Tβ4 studies to support TB-500, it is assuming, without showing it, that the fragment keeps the full molecule's properties intact.
It may keep them. It may not. This is exactly the kind of question comparative studies settle, and those studies are scarce.
| Thymosin β4 (Tβ4) | TB-500 | |
|---|---|---|
| Nature | Complete natural peptide | Synthetic fragment |
| Length | 43 amino acids | ~7 amino acids |
| Presence in the body | Ubiquitous and very abundant | Not naturally occurring |
| Its own scientific literature | Extensive | Scarce; Tβ4's is cited instead |
| Clinical development | Ophthalmic and dermal indications | None |
G-actin: the mechanism
Actin is the structural protein that forms the cytoskeleton. It exists in two states: G-actin (free monomers) and F-actin (polymerized filaments). The balance between the two determines whether a cell can change shape and move.
Thymosin β4 binds G-actin and holds it in reserve, available to polymerize where and when it is needed. That regulation underlies cell migration: to move, a cell has to take its cytoskeleton apart and rebuild it continuously.
From there come the effects described in the preclinical literature: endothelial cell migration, which translates into angiogenesis; keratinocyte migration in skin wound healing; and modulation of the inflammatory response.
At the cellular level, this is a well-characterized mechanism. What separates it from a clinical effect is the usual sequence of steps in the evidence hierarchy.
Systemic versus local: what supports the claim
Describing TB-500 as "systemic" in contrast to a "local" BPC-157 is repeated across the sector. What holds that description up deserves a closer look.
The argument has two pieces:
The molecule is small and diffuses well. A seven-amino-acid fragment spreads easily through tissue.
Thymosin β4 is ubiquitous. It sits in almost every cell rather than in one specific tissue, and the effects described in animal models show up in diverse organs.
Both pieces are reasonable. What does not exist is a human pharmacokinetic and biodistribution study confirming the description. Today the local/systemic distinction is a plausible mechanistic inference, not a measured result.
The distinction matters, because the rationale for combining it with BPC-157 is built on it.
The ophthalmic clinical program
This is the point where the family parts ways with the rest of the repair compounds, and it deserves acknowledgment.
Thymosin β4 has gone through formal clinical development at RegeneRx Biopharmaceuticals, in ophthalmic indications (ocular surface disease, corneal epithelial defects) and dermal ones.
What that means and what it does not:
It means there is a clinical file on the complete molecule, in specific indications, with registered trials. That is far more than most compounds in this category can claim.
It does not mean there is clinical evidence for TB-500, the fragment, in musculoskeletal indications. Different molecule, different indication, different route of administration. Extrapolating from an ocular surface trial to a tendinopathy is a jump the evidence does not license.
Why it gets combined with BPC-157
The hypothesis, in short: predominantly systemic action alongside predominantly local action, on complementary phases of the repair process.
It is coherent. It also has not been tested: no study of the combination exists. The full analysis is in the article devoted to that combination.
In the catalog, TB-500 does not appear as a standalone item but in combination; the analytical data are in the blend's product page.
Regulatory status and sport
TB-500 is not approved by any agency for human therapeutic use.
In sport the situation is doubly clear. Section S2 of the prohibited list covers growth factors affecting vascularization and tissue regeneration, written by function precisely to capture compounds of this type. And since no authority has approved it, it also falls under S0. Either route is enough on its own. This is developed in the article on WADA.
What the evidence does not settle
Whether the fragment matches the complete molecule. That is the underlying question, and it has no answer. Much of the literature cited to support TB-500 was done with Tβ4.
Human pharmacokinetics of the fragment. Not published.
Any musculoskeletal indication. No controlled trials.
The "systemic" description. Plausible, not measured in people.
Frequently asked questions
Are TB-500 and thymosin β4 the same thing?
No. Thymosin β4 is a natural 43-amino-acid peptide. What is TB-500, precisely? A synthetic fragment of about seven amino acids corresponding to the actin-binding region. Most of the serious literature was done with the complete molecule.
Are there clinical trials of TB-500?
For complete thymosin β4 there is clinical development in ophthalmic and dermal indications. For the fragment, and in musculoskeletal indications, no controlled trials have been published.
Does it really act systemically?
It is a reasonable inference from the size of the molecule and the ubiquity of thymosin β4, not a biodistribution figure measured in humans.
Is it banned in sport?
Yes, by two independent routes: as a growth factor affecting vascularization and regeneration (S2) and as a non-approved substance (S0). Either one is sufficient.
References
- Goldstein AL, et al. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine, 2005;11(9):421–429. DOI: 10.1016/j.molmed.2005.07.004
- Crockford D, et al. Thymosin β4: structure, function, and biological properties supporting current and future clinical applications. Annals of the New York Academy of Sciences, 2010;1194:179–189. DOI: 10.1111/j.1749-6632.2010.05492.x
- Sosne G, et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo. Experimental Eye Research, 2002;74(2):293–299. DOI: 10.1006/exer.2001.1125
- World Anti-Doping Agency. The Prohibited List, section S2. wada-ama.org
Written by the Bionic Editorial Team. Last reviewed: August 2026.
How we work: our editorial policy and source hierarchy.
This content is strictly educational and does not constitute medical advice, diagnosis or a therapeutic recommendation. The compounds mentioned are research products (Research Use Only) and are not approved by INVIMA, FDA, EMA or ANSM for therapeutic use in humans. Any health-related decision should be made with a licensed medical professional.